
Paolo Mulatero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5019460/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Increased Diagnosis of Primary Aldosteronism, Including Surgically Correctable Forms, in Centers from Five Continents. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1045-1050.	3.6	862
2	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes and Endocrinology,the, 2017, 5, 689-699.	11.4	595
3	Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes and Endocrinology,the, 2018, 6, 41-50.	11.4	582
4	Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in PrimaryÂCareÂPractice. Journal of the American College of Cardiology, 2017, 69, 1811-1820.	2.8	520
5	Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nature Genetics, 2013, 45, 440-444.	21.4	460
6	Long-Term Cardio- and Cerebrovascular Events in Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4826-4833.	3.6	348
7	Drug Effects on Aldosterone/Plasma Renin Activity Ratio in Primary Aldosteronism. Hypertension, 2002, 40, 897-902.	2.7	346
8	Prevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 454-459.	3.6	340
9	Age and Multimorbidity Predict Death Among COVID-19 Patients. Hypertension, 2020, 76, 366-372.	2.7	330
10	Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. Hypertension, 2014, 64, 354-361.	2.7	248
11	Prevalence, Clinical, and Molecular Correlates of <i>KCNJ5</i> Mutations in Primary Aldosteronism. Hypertension, 2012, 59, 592-598.	2.7	246
12	<i>KCNJ5</i> Mutations in European Families With Nonglucocorticoid Remediable Familial Hyperaldosteronism. Hypertension, 2012, 59, 235-240.	2.7	176
13	Comparison of Confirmatory Tests for the Diagnosis of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2618-2623.	3.6	174
14	The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment. Endocrine Reviews, 2018, 39, 1057-1088.	20.1	168
15	Somatic <i>ATP1A1</i> , <i>ATP2B3</i> , and <i>KCNJ5</i> Mutations in Aldosterone-Producing Adenomas. Hypertension, 2014, 63, 188-195.	2.7	151
16	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension â^—. Journal of Hypertension, 2020, 38, 1919-1928.	0.5	151
17	Roles of Clinical Criteria, Computed Tomography Scan, and Adrenal Vein Sampling in Differential Diagnosis of Primary Aldosteronism Subtypes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1366-1371.	3.6	149
18	Impact of Different Diagnostic Criteria During Adrenal Vein Sampling on Reproducibility of Subtype Diagnosis in Patients With Primary Aldosteronism. Hypertension, 2010, 55, 667-673.	2.7	140

#	Article	IF	CITATIONS
19	Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. Lancet Diabetes and Endocrinology,the, 2015, 3, 296-303.	11.4	134
20	Guidelines for primary aldosteronism. Journal of Hypertension, 2016, 34, 2253-2257.	0.5	134
21	Prevalence and Characteristics of Familial Hyperaldosteronism. Hypertension, 2011, 58, 797-803.	2.7	128
22	International Histopathology Consensus for Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 42-54.	3.6	127
23	Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends in Endocrinology and Metabolism, 2005, 16, 114-119.	7.1	125
24	Diagnosis of Glucocorticoid-Remediable Aldosteronism in Primary Aldosteronism: Aldosterone Response to Dexamethasone and Long Polymerase Chain Reaction for Chimeric Gene. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2573-2575.	3.6	121
25	Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Molecular and Cellular Endocrinology, 2015, 411, 146-154.	3.2	115
26	Diagnosis and treatment of primary aldosteronism. Lancet Diabetes and Endocrinology,the, 2021, 9, 876-892.	11.4	106
27	18-Hydroxycorticosterone, 18-Hydroxycortisol, and 18-Oxocortisol in the Diagnosis of Primary Aldosteronism and Its Subtypes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 881-889.	3.6	105
28	Role of KCNJ5 in familial and sporadic primary aldosteronism. Nature Reviews Endocrinology, 2013, 9, 104-112.	9.6	101
29	Rapid Cortisol Assay during Adrenal Vein Sampling in Patients with Primary Aldosteronism. Clinical Chemistry, 2007, 53, 1968-1971.	3.2	95
30	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 641-649.	2.7	94
31	Psychological Assessment of Primary Aldosteronism: A Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E878-E883.	3.6	91
32	Diagnosis and treatment of low-renin hypertension. Clinical Endocrinology, 2007, 67, 324-334.	2.4	89
33	The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme. Nature Structural and Molecular Biology, 1997, 4, 32-35.	8.2	88
34	Effect of Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism. Hypertension, 2012, 59, 840-846.	2.7	87
35	A Novel Y152C KCNJ5 Mutation Responsible for Familial Hyperaldosteronism Type III. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1861-E1865.	3.6	86
36	Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. Journal of Hypertension, 2008, 26, 1577-1582.	0.5	82

#	Article	IF	CITATIONS
37	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension, 2018, 71, 317-325.	2.7	77
38	Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension â^—. Journal of Hypertension, 2020, 38, 1929-1936.	0.5	74
39	CYP11B2Gene Polymorphisms in Idiopathic Hyperaldosteronism. Hypertension, 2000, 35, 694-698.	2.7	72
40	Liddle Syndrome: Review of the Literature and Description of a New Case. International Journal of Molecular Sciences, 2018, 19, 812.	4.1	69
41	The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. International Journal of Cardiology: Hypertension, 2020, 5, 100029.	2.2	69
42	Glucocorticoid Remediable Aldosteronism: Low Morbidity and Mortality in a Four-Generation Italian Pedigree. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3187-3191.	3.6	67
43	The Primary Aldosteronism Surgical Outcome Score for the Prediction of Clinical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Annals of Surgery, 2020, 272, 1125-1132.	4.2	66
44	Visinin-Like 1 Is Upregulated in Aldosterone-Producing Adenomas With <i>KCNJ5</i> Mutations and Protects From Calcium-Induced Apoptosis. Hypertension, 2012, 59, 833-839.	2.7	64
45	Clinical Management and Outcomes of Adrenal Hemorrhage Following Adrenal Vein Sampling in Primary Aldosteronism. Hypertension, 2016, 67, 146-152.	2.7	63
46	Renal damage in primary aldosteronism. Journal of Hypertension, 2020, 38, 3-12.	0.5	63
47	Aldosterone Suppression on Contralateral Adrenal During Adrenal Vein Sampling Does Not Predict Blood Pressure Response After Adrenalectomy. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4158-4166.	3.6	62
48	Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism. Journal of Hypertension, 2016, 34, 920-927.	0.5	61
49	Prevalence of Hypokalemia and Primary Aldosteronism in 5100 Patients Referred to a Tertiary Hypertension Unit. Hypertension, 2020, 75, 1025-1033.	2.7	60
50	Captopril Test Can Give Misleading Results in Patients With Suspect Primary Aldosteronism. Hypertension, 2007, 50, e26-7.	2.7	55
51	A Case of Severe Hyperaldosteronism Caused by a De Novo Mutation Affecting a Critical Salt Bridge Kir3.4 Residue. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E114-E118.	3.6	53
52	Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism. JAMA Network Open, 2020, 3, e2016209.	5.9	53
53	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 650-657.	2.7	51
54	Concurrent primary aldosteronism and subclinical cortisol hypersecretion. Journal of Hypertension, 2011, 29, 1773-1777.	0.5	50

#	Article	IF	CITATIONS
55	ls Primary Aldosteronism Still Largely Unrecognized?. Hormone and Metabolic Research, 2017, 49, 908-914.	1.5	50
56	Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Molecular and Cellular Endocrinology, 2014, 394, 13-20.	3.2	48
57	Development and Validation of Prediction Models for Subtype Diagnosis of Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3706-e3717.	3.6	47
58	α ₁ -Adrenergic Receptor Subtypes in Human Peripheral Blood Lymphocytes. Hypertension, 1999, 33, 708-712.	2.7	46
59	Differential diagnosis of primary aldosteronism subtypes. Current Hypertension Reports, 2009, 11, 217-223.	3.5	46
60	GENETICS IN ENDOCRINOLOGY: The expanding genetic horizon of primary aldosteronism. European Journal of Endocrinology, 2018, 178, R101-R111.	3.7	46
61	Understanding primary aldosteronism: impact of next generation sequencing and expression profiling. Molecular and Cellular Endocrinology, 2015, 399, 311-320.	3.2	45
62	Primary Aldosteronism and Obstructive Sleep Apnea. Hypertension, 2019, 74, 1532-1540.	2.7	45
63	Teratocarcinoma-Derived Growth Factor-1 Is Upregulated in Aldosterone-Producing Adenomas and Increases Aldosterone Secretion and Inhibits Apoptosis In Vitro. Hypertension, 2010, 55, 1468-1475.	2.7	43
64	Mineralocorticoid Receptor Blockade in the Protection of Target Organ Damage. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2006, 4, 75-91.	1.0	40
65	Is There a Role for Genomics in the Management of Hypertension?. International Journal of Molecular Sciences, 2017, 18, 1131.	4.1	40
66	Subtype Diagnosis of Primary Aldosteronism: Is Adrenal Vein Sampling Always Necessary?. International Journal of Molecular Sciences, 2017, 18, 848.	4.1	40
67	UHPLC–MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients. Journal of Pharmaceutical and Biomedical Analysis, 2016, 129, 535-541.	2.8	39
68	Deletion Hybrid Genes, due to Unequal Crossing Over between <i>CYP11B1</i> (11β-Hydroxylase) and <i>CYP11B2</i> (Aldosterone Synthase) Cause Steroid 11β-Hydroxylase Deficiency and Congenital Adrenal Hyperplasia ¹ . Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3197-3201.	3.6	38
69	Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 105-108.	2.2	37
70	<i>KCNJ5</i> Mutations Are the Most Frequent Genetic Alteration in Primary Aldosteronism. Hypertension, 2015, 65, 507-509.	2.7	34
71	Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides. Kidney International, 2005, 67, 631-637.	5.2	33
72	UHPLC–MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples. Journal of Pharmaceutical and Biomedical Analysis, 2017, 142, 279-285.	2.8	33

#	Article	IF	CITATIONS
73	The SPARTACUS Trial: Controversies and Unresolved Issues. Hormone and Metabolic Research, 2017, 49, 936-942.	1.5	33
74	Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism. Hypertension, 2020, 75, 163-172.	2.7	33
75	Diagnostic approach to lowâ€renin hypertension. Clinical Endocrinology, 2018, 89, 385-396.	2.4	32
76	Mutation affecting the conserved acidic WNK1 motif causes inherited hyperkalemic hyperchloremic acidosis. Journal of Clinical Investigation, 2020, 130, 6379-6394.	8.2	32
77	Blood Pressure in Patients with Primary Aldosteronism Is Influenced by Bradykinin B ₂ Receptor and α-Adducin Gene Polymorphisms. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3337-3343.	3.6	30
78	Diagnosis and treatment of primary aldosteronism. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 3-9.	5.7	30
79	Histological Characterization of Aldosterone-producing Adrenocortical Adenomas with Different Somatic Mutations. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e282-e289.	3.6	29
80	Genetics of primary aldosteronism. Journal of Hypertension, 2004, 22, 663-670.	0.5	28
81	Classification of microadenomas in patients with primary aldosteronism by steroid profiling. Journal of Steroid Biochemistry and Molecular Biology, 2019, 189, 274-282.	2.5	28
82	Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study. Pharmacogenomics, 2014, 15, 1643-1652.	1.3	27
83	1α,25-Dihydroxyvitamin D3 inhibits the human H295R cell proliferation by cell cycle arrest: A model for a protective role of vitamin D receptor against adrenocortical cancer. Journal of Steroid Biochemistry and Molecular Biology, 2014, 140, 26-33.	2.5	26
84	Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy. Hypertension Research, 2020, 43, 500-510.	2.7	26
85	QT interval in patients with primary aldosteronism and low-renin essential hypertension. Journal of Hypertension, 2006, 24, 2459-2464.	0.5	25
86	Adrenal Venous Sampling–Guided Adrenalectomy Rates in Primary Aldosteronism: Results of an International Cohort (AVSTAT). Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1400-e1407.	3.6	25
87	Polyuric-polydipsic syndrome in a pediatric case of non-glucocorticoid remediable familial hyperaldosteronism. Endocrine Journal, 2012, 59, 497-502.	1.6	24
88	Mouse Models of Primary Aldosteronism: From Physiology to Pathophysiology. Endocrinology, 2017, 158, 4129-4138.	2.8	24
89	Characterization and Gene Expression Analysis of Serum-Derived Extracellular Vesicles in Primary Aldosteronism. Hypertension, 2019, 74, 359-367.	2.7	23
90	Histopathological and genetic characterization of aldosterone-producing adenomas with concurrent subclinical cortisol hypersecretion: a case series. Endocrine, 2017, 58, 503-512.	2.3	22

#	Article	IF	CITATIONS
91	Evaluation of primary aldosteronism. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 188-193.	2.3	21
92	Aldosterone effects on glomerular structure and function. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 730-738.	1.7	20
93	Nomogram-Based Preoperative Score for Predicting Clinical Outcome in Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4382-e4392.	3.6	20
94	A time-resolved fluoroimmunoassay for 18-oxocortisol and 18-hydroxycortisol. Journal of Steroid Biochemistry and Molecular Biology, 2002, 82, 83-88.	2.5	19
95	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1111-e1128.	3.6	19
96	Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. Molecular and Cellular Endocrinology, 2012, 355, 162-168.	3.2	18
97	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3374-e3383.	3.6	17
98	The spectrum of low-renin hypertension. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101399.	4.7	17
99	Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3655-e3664.	3.6	16
100	Development of a Prediction Score to Avoid Confirmatory Testing in Patients With Suspected Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1708-1716.	3.6	16
101	Noninvasive assessment of spontaneous baroreflex sensitivity in patients with liver cirrhosis. Liver, 1998, 18, 420-426.	0.1	15
102	Is Familial Hyperaldosteronism Underdiagnosed in Hypertensive Children?. Hypertension, 2011, 57, 1053-1055.	2.7	15
103	10 good reasons why adrenal vein sampling is the preferred method for referring primary aldosteronism patients for adrenalectomy. Journal of Hypertension, 2019, 37, 603-611.	0.5	14
104	Primary Aldosteronism and Obstructive Sleep Apnea: Casual Association or Pathophysiological Link?. Hormone and Metabolic Research, 2020, 52, 366-372.	1.5	14
105	Characterization of Circulating Extracellular Vesicle Surface Antigens in Patients With Primary Aldosteronism. Hypertension, 2021, 78, 726-737.	2.7	14
106	Glucocorticoid Remediable Aldosteronism: Low Morbidity and Mortality in a Four-Generation Italian Pedigree. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3187-3191.	3.6	14
107	Primary aldosteronism in the primary care setting. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 155-159.	2.3	12
108	Primary Aldosteronism in the Elderly. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2320-e2326.	3.6	12

#	Article	IF	CITATIONS
109	Genetic and Potential Autoimmune Triggers of Primary Aldosteronism. Hypertension, 2015, 66, 248-253.	2.7	10
110	Clinical Score and Machine Learning-Based Model to Predict Diagnosis of Primary Aldosteronism in Arterial Hypertension. Hypertension, 2021, 78, 1595-1604.	2.7	10
111	Urinary Metabolic Signature of Primary Aldosteronism: Gender and Subtypeâ€ S pecific Alterations. Proteomics - Clinical Applications, 2019, 13, e1800049.	1.6	9
112	Diagnosis and Treatment of Unilateral Forms of Primary Aldosteronism. Current Hypertension Reviews, 2013, 9, 156-165.	0.9	9
113	World Hypertension Day 2021 in Italy: Results of a Nationwide Survey. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 353-359.	2.2	9
114	Primary aldosteronism in pregnancy. Reviews in Endocrine and Metabolic Disorders, 2023, 24, 39-48.	5.7	9
115	BEX1 Is Differentially Expressed in Aldosterone-Producing Adenomas and Protects Human Adrenocortical Cells From Ferroptosis. Hypertension, 2021, 77, 1647-1658.	2.7	8
116	Prediction of hyperaldosteronism subtypes when adrenal vein sampling is unilaterally successful. European Journal of Endocrinology, 2020, 183, 657-667.	3.7	8
117	Supervised and unsupervised learning to define the cardiovascular risk of patients according to an extracellular vesicle molecular signature. Translational Research, 2022, , .	5.0	8
118	Quality of life in primary aldosteronism: A prospective observational study. European Journal of Clinical Investigation, 2021, 51, e13419.	3.4	7
119	Hypertension, genotype and oral contraceptives. Pharmacogenomics, 2002, 3, 57-63.	1.3	6
120	Aldosterone as an Independent Factor in Cerebrovascular Damage. Clinical and Experimental Hypertension, 2008, 30, 785-797.	1.3	6
121	A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples. Journal of Pharmacological and Toxicological Methods, 2018, 94, 29-35.	0.7	6
122	Role of Cryptochrome-1 and Cryptochrome-2 in Aldosterone-Producing Adenomas and Adrenocortical Cells. International Journal of Molecular Sciences, 2018, 19, 1675.	4.1	5
123	Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1262-E1269.	3.6	4
124	May Measurement Month 2018: an analysis of blood pressure screening results from Italy. European Heart Journal Supplements, 2020, 22, H70-H73.	0.1	4
125	May Measurement Month 2019: an analysis of blood pressure screening results from Italy. European Heart Journal Supplements, 2021, 23, B77-B81.	0.1	4
126	Hyperaldosteronism: How to Discriminate Among Different Disease Forms?. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 203-208.	2.2	3

#	Article	IF	CITATIONS
127	A Case of Adrenal Vein Sampling in Primary Aldosteronism With Homolateral Suppression. Journal of the Endocrine Society, 2017, 1, 401-406.	0.2	3
128	Is Renin-Based Treatment a Reasonable Strategy to Treat Essential Hypertension?. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 121-125.	2.2	2
129	Evolution of computed tomography-detectable adrenal nodules in patients with bilateral primary aldosteronism. Endocrine, 2016, 54, 826-829.	2.3	2
130	Ca2+ channels of the L-type in peripheral blood lymphocytes of essential hypertensives. American Journal of Hypertension, 1999, 12, 40-46.	2.0	1
131	Antihypertensive Bridge Therapy by Continuous Drug Infusion With an Elastomeric Pump in Device-Resistant Hypertension. Hypertension, 2016, 67, e3-4.	2.7	1
132	Genetics of Familial Hyperaldosteronism. , 2019, , 623-630.		1
133	The Renin-Angiotensin System, Capri 2005. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 91-108.	2.2	0
134	Controversies on the Diagnosis of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 173-178.	2.2	0
135	Issues in the Diagnosis and Treatment of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 73-82.	2.2	0
136	Assessment of Anti-Hypertensive Drug Adherence by Serial Aldosterone-To-Renin Ratio Measurement. Frontiers in Pharmacology, 2021, 12, 668843.	3.5	0
137	Response to Letter to the Editor from Rossi and Rossitto: "Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism― Journal of Clinical Endocrinology and Metabolism, 2022, 107, e896-e897.	3.6	0
138	SUN-LB97 Targeted Metabolomics as a Screening Tool in the Diagnosis of Endocrine Hypertension. Journal of the Endocrine Society, 2020, 4, .	0.2	0